GLP-1 cost in 2026: what you actually pay
GLP-1 medications run from about $199 a month for compounded semaglutide cash-pay to over $1,300 a month for branded Wegovy or Zepbound without insurance. The price you see on a homepage is rarely the price you pay at maintenance dose. We walk through every legitimate path, what each one costs in year one and ongoing, and where the hidden fees hide.
The short version
Cash-pay branded GLP-1s (Wegovy, Zepbound) run roughly $1,000 to $1,350 a month at list price. Manufacturer-direct cash programs (NovoCare, LillyDirect) bring that to about $499 to $650 a month for eligible patients. Compounded semaglutide through a US telehealth program runs $199 to $349 a month at maintenance dose. Compounded tirzepatide runs $349 to $549. Year-one all-in cost, including labs, intake and titration, ranges from about $2,500 (cheapest legitimate compounded path) to roughly $16,000 (full list-price branded with no coupon). The single biggest decision is whether you have a commercial plan that covers GLP-1 for obesity; if you do, you pay a copay of $25 to $100 a month and everything below this paragraph is mostly academic.
Key facts
| Path | Maintenance cost / mo | Year-one all-in | Source |
|---|---|---|---|
| Wegovy, list price, no insurance | $1,349 | $16,800 | NovoCare list price page |
| Zepbound, list price, no insurance | $1,086 | $13,500 | LillyDirect pricing |
| Wegovy, NovoCare cash program | $499 | $6,200 | NovoCare, updated quarterly |
| Zepbound, LillyDirect vial | $349 to $499 | $4,800 to $6,200 | LillyDirect self-pay program |
| Compounded semaglutide, US telehealth | $199 to $349 | $2,500 to $4,400 | GLP Chart Price Index |
| Compounded tirzepatide, US telehealth | $349 to $549 | $4,400 to $7,000 | GLP Chart Price Index |
| Commercial insurance with coverage | $25 to $100 copay | $300 to $1,200 | KFF analysis |
| Medicare Part D, cardiovascular indication | $50 to $200 copay | $600 to $2,400 | CMS Part D |
Prices verified by purchase-flow walkthroughs on the quarterly Price Index and by direct review of manufacturer pricing pages. All numbers reflect maintenance-dose, ongoing cost, not the starter-dose teaser most programs feature on their homepage.
Branded GLP-1 cash-pay prices
The four branded GLP-1s that matter for cash-pay decisions are Wegovy (semaglutide 2.4 mg) and Ozempic (semaglutide up to 2.0 mg) from Novo Nordisk, and Zepbound (tirzepatide) and Mounjaro (tirzepatide) from Eli Lilly. Wegovy and Zepbound carry the obesity indication. Ozempic and Mounjaro carry the type 2 diabetes indication. They are the same molecules at the same maintenance doses, dispensed under different brand names and different FDA labels.
List prices on the manufacturer pages have stayed remarkably stable since 2023. Wegovy lists at $1,349 a month, Zepbound at $1,086, Ozempic at $968, and Mounjaro at $1,069. These are wholesale acquisition cost (WAC) numbers; what an uninsured patient actually pays at a retail pharmacy is generally within 10 percent of WAC, sometimes slightly below it through GoodRx-style coupons. The Lilly and Novo Nordisk direct-to-consumer cash programs are the only path under $500 a month for the branded molecule. See Wegovy drug page, Zepbound drug page, Ozempic drug page and Mounjaro drug page for the per-drug pricing breakdown and clinical context.
Rybelsus (oral semaglutide, 3 mg, 7 mg, 14 mg) is the outlier. List price runs about $999 a month, and the efficacy at the 14 mg dose is roughly equivalent to Ozempic 1.0 mg injectable, which is a half-step below the maintenance dose most weight-loss patients reach. Rybelsus is rarely the cost-effective choice for weight management unless the patient has a strong needle phobia. The branded oral semaglutide is in a different bucket from compounded oral semaglutide, which is a different drug entirely (different bioavailability, different absorption profile).
Compounded semaglutide and tirzepatide
Compounded GLP-1 is the same active ingredient (semaglutide or tirzepatide) prepared by a 503A or 503B compounding pharmacy under a prescription. It is not FDA-approved as a finished drug product, but the active ingredient is the same molecule used in the branded version. The FDA placed both molecules on the drug-shortage list in 2022 and 2023, which opened a legal pathway for compounding pharmacies to prepare them. Tirzepatide came off the shortage list in October 2024, and semaglutide came off in February 2025. Compounding under section 503A continues for individual patient-specific prescriptions, but 503B bulk compounding for these molecules is now restricted. See the FDA's statement on semaglutide compounding and the deeper context in our explainer on compounded vs FDA-approved semaglutide.
Cash-pay price for compounded semaglutide in the US telehealth market settles between $199 and $349 a month at maintenance dose. Compounded tirzepatide settles between $349 and $549. The price floor is set by the cost of the active pharmaceutical ingredient (API) plus pharmacy compounding cost plus telehealth program margin. Anyone offering compounded semaglutide below $150 a month is either subsidizing through introductory pricing that resets after the first month, sourcing API from unregulated suppliers, or both. The legitimate floor is around $199.
Starter dose vs maintenance dose
The single most common mistake patients make when comparing cash-pay programs is anchoring on the starter-dose price. Semaglutide titrates from 0.25 mg to 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg over four to five months. Tirzepatide titrates from 2.5 mg to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg over five to six months. At each step the dose roughly doubles. Many programs price the starter dose at $149 to $199 and the maintenance dose at $299 to $499, and they feature the starter price on the homepage. We list both numbers on every program page; see Mochi, Henry Meds, Hims and Ro for the pricing structure side by side. Our explainer on how GLP-1 telehealth pricing actually works walks through the math.
Year one vs ongoing cost
Year-one cost is higher than ongoing cost in almost every legitimate path. The first three months of titration use lower doses (sometimes priced lower), but the program-side overhead of intake, labs and additional provider visits frontloads cost. After month six, most patients are on maintenance dose and the monthly cost stabilizes. A patient who stays on the medication for the long-term horizon recommended by the STEP-1 trial published in the New England Journal of Medicine and confirmed by SURMOUNT-1 is looking at a cumulative cost of $30,000 to $100,000 over five years on a fully cash-pay branded path, versus $12,000 to $20,000 on a compounded path. Whether to stay on the medication after weight loss is a separate clinical question we cover in do I stay on GLP-1 forever and what happens when you stop.
How prices are verified
We verify prices three ways. First, we pull the program's published pricing page weekly and flag any change. Second, we run an anonymous purchase-flow walkthrough on each program quarterly: real patient, real intake, real receipt. Third, we cross-reference against the program's terms of service and welcome email, which sometimes contradict the homepage pricing. Where the homepage and the actual checkout diverge, we use the checkout price on the chart. Programs are not notified before a walkthrough. The full process is documented on the methodology page and the quarterly results land on the Price Index.
Maintenance-dose comparison across programs
The chart on the homepage ranks every program against the same five criteria. For cost-focused decisions, the rank order changes meaningfully once you filter by maintenance-dose price. The cheapest legitimate programs at maintenance dose in 2026 are Mochi (around $199 at the lowest tier), Henry Meds ($199 to $299 compounded), Ivim Health (around $279), and Eden (around $249 introductory, $349 ongoing). The most expensive legitimate programs are the ones bundled with intensive behavioral coaching: Form Health, Calibrate and Embla at $300 to $500 a month on top of medication cost. We rank cheapest on the cheapest GLP-1 program cluster, and the under-200 cluster lives at best GLP-1 under $200.
Hidden fees and the price-at-checkout problem
The hidden-fee picture is more annoying than expensive. Common gotchas: a mandatory $50 to $120 lab order at intake (some programs include it, some bill separately), a separate $40 to $90 charge for the initial video visit even on programs that advertise the visit as free, dose-escalation visit fees at $25 to $75 per step, missed-dose reschedule fees, and shipping. The lock-in side is more financially material: many programs require a three-month or six-month commitment with the upfront fee non-refundable on cancellation. We cover the structural traps in the seven contract traps in weight loss program terms and the lock-in glossary in what no lock-in actually means.
The insurance vs cash decision
If you have a commercial plan that covers Wegovy or Zepbound for obesity, your out-of-pocket is almost always lower than any cash-pay path. The friction is the prior authorization. The PA process takes one to six weeks, requires a documented six-month lifestyle intervention on most plans, and is denied on first submission 30 to 50 percent of the time. We walk through the process in the GLP-1 insurance pillar and provide payer-specific templates at Aetna, Cigna, UnitedHealthcare and Anthem BCBS. The HSA and FSA paths can soften the cash-pay bill by 25 to 40 percent in marginal tax savings; details in HSA and FSA for GLP-1.
Medicare and Medicaid pricing
Medicare Part D does not cover any GLP-1 for the obesity indication, under the same federal statute that excludes weight-loss medications from Part D since the program's inception. The exception is that Wegovy picked up a Part D coverage path in March 2024 for cardiovascular risk reduction in patients with established cardiovascular disease, following the SELECT trial published in NEJM. Zepbound picked up a Part D path in December 2024 for moderate-to-severe sleep apnea following SURMOUNT-OSA. Both are full Part D drugs for those indications; copays run $50 to $200 in the initial phase, then drop after the catastrophic threshold under the 2025 Inflation Reduction Act provisions. See CMS guidance on the Inflation Reduction Act for the copay phase changes and the per-drug pages for indication-specific PA language.
Medicaid coverage varies by state. Roughly 15 states cover Wegovy or Zepbound for obesity with prior authorization. The remaining 35 states cover only for diabetes (Ozempic, Mounjaro) and exclude the obesity brands entirely. The state-by-state breakdown is current at Medicaid GLP-1 coverage by state; California Medi-Cal removed obesity coverage in 2026, and Massachusetts and Pennsylvania expanded coverage the same year. The deeper context is in Medicaid GLP-1 coverage breakdown.
Cheapest legitimate path by buyer scenario
For an uninsured patient with no clinical comorbidities, compounded semaglutide through a US telehealth program is the floor at around $199 to $349 a month. For an insured patient with BMI 30 or above and a documented comorbidity, the branded path through the prior authorization process is almost always cheaper in copay terms once approved. For a Medicare patient with established cardiovascular disease, Wegovy on Part D is the path. For a Medicare patient with moderate-to-severe sleep apnea, Zepbound on Part D is the path. For a patient in a non-covered Medicaid state, compounded is the only realistic option short of manufacturer patient-assistance programs, which we catalog in GLP-1 patient assistance programs. For an under-25 BMI patient (off-label microdose), see the editorial limits in microdosing evidence and longevity microdosing; we do not encourage it without clinician oversight.
What trial data says about cost-effectiveness
The cost-effectiveness analyses published in peer-reviewed journals consistently find that branded GLP-1s at US list prices are not cost-effective by the $100,000 to $150,000 per quality-adjusted life year (QALY) threshold conventionally used in US health-economic analysis. The same analyses find that GLP-1s would be cost-effective at roughly 30 to 50 percent of US list price, which is approximately the price patients pay in Canada and Western Europe. The Institute for Clinical and Economic Review's 2022 assessment, updated in 2024, is the canonical reference; see ICER obesity assessment for the methodology. The implication is patient-level rather than policy-level: the medication generates enormous clinical value, but the US price structure transfers most of that value to the manufacturer rather than the patient. Compounded paths and manufacturer cash programs partially close that gap.
The international price contrast is large and well-documented. The Peterson-KFF Health System Tracker published a 2024 cross-country analysis showing Wegovy list prices roughly five to ten times higher in the US than in Canada, the UK, Germany or Australia for the same patient-administered dose. See Peterson-KFF analysis for the per-country figures. The Congressional Budget Office's 2024 score of proposed Medicare anti-obesity coverage estimated $35 billion in additional federal spending over 10 years if Medicare were to cover GLP-1 for obesity at current list prices; see the CBO estimate. Both numbers reinforce the patient-level point: the medication's price reflects the US market structure, not the underlying cost of producing the drug, and patient-level choices about cash-pay vs insurance vs compounded paths sit downstream of that structural fact.
What to do next
If you are insurance-shopping, start with the insurance pillar and pick the PA template that matches your plan. If you are cash-pay, start with the cheapest programs cluster and the under-200 cluster, then verify maintenance-dose pricing on the individual program page before signing up. If you are Medicare or Medicaid, the path depends on indication; the insurance pillar covers both. If you want a single-screen comparison, the homepage chart sorts by overall score and by maintenance-dose price.
Or skip the reading and run the numbers directly. Three calculators answer the most common pricing questions: cost comparison across every program, savings vs your current insurance copay, and BMI plus program matching by state.
